Urocortin: Advancing the neurohumoral hypothesis of heart failure

Circulation

Volumn 112, Issue 23, 2005, Pages 3544-3546

  Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Editorials; Heart failure; Peptides

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; UROCORTIN; UROCORTIN II;

ANIMAL MODEL; AUTOCRINE EFFECT; EDITORIAL; HEART FAILURE; HEART PERFORMANCE; HUMAN; HYPOTHESIS; KIDNEY FUNCTION; MEDICAL RESEARCH; NEUROENDOCRINE SYSTEM; NEUROHUMORAL HYPOTHESIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; THERAPY; ANIMAL; BLOOD; CONGESTIVE HEART FAILURE; HEART MUSCLE CELL; NOTE; PHYSIOLOGY;

ANIMALS; AUTOCRINE COMMUNICATION; CORTICOTROPIN-RELEASING HORMONE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION;

EID: 33644875609     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.584441     Document Type: Editorial

References (20)

1. Vaughn J, Donaldson C, Bittencourt J, Perrin MN, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378:287-292.
2. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type CRF receptors. Proc Nat Acad Sci U S A. 2001;98:2843-2848.
3. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Nat Acad Sci U S A. 2004;101:3697-3702.
4. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab. 2002;87:340-346.
5. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol. 1997;272:H2115-H2122.
6. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol. 2002;40:1495-1505.
7. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation. 2005;112:3624-3632.
8. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
9. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC Jr. Natriuretic and anti-aldosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005;67:1723-1730.
10. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001;7:605-611.
11. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, Frampton CM, Richards AM. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci. 2005;109:381-388.
12. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728-736.
13. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Hermann HC, McCullough PA, for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
14. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Peter JG, Burnett JC Jr. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol. 1998;274:H1684-H1689.
15. Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, Nakao K, Kawamura M. Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides. 2005;July 6(Epub ahead of print).
16. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr. Oral human BNP activates cGMP and decreases mean arterial pressure. Circulation. 2005;112:836-840.
17. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-141.
18. Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, Van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
19. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
20. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.